{
    "id": "b3b6c9d3-c3cd-4d93-999e-3faf5d401282",
    "indications": {
        "text": "blincyto bispecific cd19-directed cd3 t-cell engager indicated treatment adult pediatric patients one month older : cd19-positive b-cell precursor acute lymphoblastic leukemia ( ) first second complete remission minimal residual disease ( mrd ) greater equal 0.1 % . ( 1.1 ) relapsed refractory cd19-positive b-cell precursor acute lymphoblastic leukemia ( ) . ( 1.2 ) cd19-positive philadelphia chromosome-negative b-cell precursor acute lymphoblastic leukemia ( ) consolidation phase multiphase chemotherapy . ( 1.3 )",
        "doid_entities": [
            {
                "text": "acute lymphoblastic leukemia (DOID:9952)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9952"
            },
            {
                "text": "lymphoblastic leukemia (DOID:1037)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1037"
            },
            {
                "text": "leukemia (DOID:1240)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1240"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "acute lymphoblastic leukemia",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_513"
            }
        ]
    },
    "contraindications": {
        "text": "treatment mrd-positive b-cell precursor - full prescribing information recommended dose patient weight schedule . ( 2.1 ) - hospitalization recommended first 3 days first cycle first 2 days second cycle . ( 2.1 ) - premedicate prednisone equivalent dexamethasone . ( 2.1 ) treatment relapsed refractory b-cell precursor - full prescribing information recommended dose patient weight schedule . ( 2.2 ) - hospitalization recommended first 9 days first cycle first 2 days second cycle . ( 2.2 ) - premedicate dexamethasone . ( 2.2 ) treatment b-cell precursor consolidation phase - full prescribing information recommended dose patient weight schedule . ( 2.3 ) - hospitalization recommended first 3 days first cycle first 2 days second cycle . ( 2.3 ) - premedicate dexamethasone . ( 2.3 ) refer full prescribing information important preparation information . ( 2.5 ) administer continuous intravenous infusion constant flow rate using infusion pump . - instructions infusion 24 hours 48 hours . - instructions infusion 72 hours , 96 hours , 7 days using bacteriostatic 0.9 % sodium chloride injection ( containing 0.9 % benzyl alcohol ) . option recommended patients weighing less 5.4 kg .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "blincyto package ( ndc 55513-160-01 ) contains : one blincyto ( blinatumomab ) injection 35 mcg single-dose vial containing sterile , preservative-free , white off-white lyophilized powder one iv solution stabilizer 10 ml single-dose glass vial containing sterile , preservative-free , colorless slightly yellow , clear solution .",
    "adverseReactions": "blincyto contraindicated patients known hypersensitivity blinatumomab component product formulation .",
    "ingredients": [],
    "organization": "Amgen, Inc",
    "name": "BLINCYTO",
    "effectiveTime": "20250429",
    "indications_original": "BLINCYTO is a bispecific CD19-directed CD3 T-cell engager indicated for the treatment of adult and pediatric patients one month and older with: CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%. ( 1.1 ) Relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL). ( 1.2 ) CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multiphase chemotherapy. ( 1.3 )",
    "contraindications_original": "For the treatment of MRD-positive B-cell Precursor ALL - See Full Prescribing Information for recommended dose by patient weight and schedule. ( 2.1 ) - Hospitalization is recommended for the first 3 days of the first cycle and the first 2 days of the second cycle. ( 2.1 ) - Premedicate with prednisone or equivalent dexamethasone. ( 2.1 ) For the treatment of Relapsed or Refractory B-cell Precursor ALL - See Full Prescribing Information for recommended dose by patient weight and schedule. ( 2.2 ) - Hospitalization is recommended for the first 9 days of the first cycle and the first 2 days of the second cycle. ( 2.2 ) - Premedicate with dexamethasone. ( 2.2 ) For the treatment of B-cell Precursor ALL in the Consolidation Phase - See Full Prescribing Information for recommended dose by patient weight and schedule. ( 2.3 ) - Hospitalization is recommended for the first 3 days of the first cycle and the first 2 days of the second cycle. ( 2.3 ) - Premedicate with dexamethasone. ( 2.3 ) Refer to Full Prescribing Information for important preparation and administration information. ( 2.5 ) Administer as a continuous intravenous infusion at a constant flow rate using an infusion pump. - See Instructions for Use for infusion over 24 hours or 48 hours. - See Instructions for Use for infusion over 72 hours, 96 hours, or 7 days using Bacteriostatic 0.9% Sodium Chloride Injection (containing 0.9% benzyl alcohol). This option is not recommended for patients weighing less than 5.4 kg.",
    "warningsAndPrecautions_original": "Each BLINCYTO package (NDC 55513-160-01) contains:\n                  \n                     One BLINCYTO (blinatumomab) for injection 35 mcg single-dose vial containing a sterile, preservative-free, white to off-white lyophilized powder and\n                     One IV Solution Stabilizer 10 mL single-dose glass vial containing a sterile, preservative-free, colorless to slightly yellow, clear solution.",
    "adverseReactions_original": "BLINCYTO is contraindicated in patients with known hypersensitivity to blinatumomab or to any component of the product formulation.",
    "drug": [
        {
            "name": "BLINCYTO"
        }
    ]
}